EQS-Adhoc

Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor

EQS-Ad-hoc: Formycon AG / Key word(s): Corporate Action/Capital Increase Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor 29-Jan-2024 / 22:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor

Munich, 29 January 2024 – Today, the management board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) ("Company" or "Formycon"), with the consent of the Company's supervisory board, resolved to increase the Company's share capital against cash contributions by issuing new no par-value bearer shares of the Company ("New Shares"), partially utilizing the authorized capital and excluding the shareholders' subscription rights ("Capital Increase"). Through the Capital Increase, the Company's share capital will be increased from currently EUR 16,053,025.00 by EUR 1,603,877.00 to EUR 17,656,902.00 by issuing 1,603,877 new no par-value bearer shares with a notional value in the Company’s share capital of EUR 1.00 per share. The gross proceeds from the Capital Increase amount to approximately EUR 82.84 million.

All New Shares were subscribed by Gedeon Richter Plc. (“Gedeon Richter"), a Hungary based major multinational specialty pharmaceutical company with core competences in research and manufacturing, in a private placement under exclusion of the shareholders' subscription rights at an issue price of EUR 51.65 per New Share representing the mean average value between today’s XETRA closing price and the volume-weighted average price of the Company's shares over the last thirty trading days. Following the Capital Increase, Gedeon Richter will hold about 9.08% of the Company's share capital and be subject to a customary lock-up obligation of 180 days.